BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31512057)

  • 1. Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
    Bozdag Z; Tutar E; Dizibuyuk OF; Bakir K
    Pathol Oncol Res; 2020 Jul; 26(3):1651-1656. PubMed ID: 31512057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
    Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
    Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
    Klebe S; Swalling A; Jonavicius L; Henderson DW
    J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
    Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
    Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
    Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
    Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer.
    Ryan PJ; Oates JL; Crocker J; Stableforth DE
    Respir Med; 1997 Jan; 91(1):57-60. PubMed ID: 9091974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfated Glycans Recognized by S1 Monoclonal Antibody can Serve as a Diagnostic Marker for Malignant Pleural Mesothelioma.
    Nakashima K; Sakai Y; Hoshino H; Umeda Y; Kawashima H; Sekido Y; Ishizuka T; Kobayashi M
    Lung; 2022 Jun; 200(3):339-346. PubMed ID: 35394203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
    Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
    Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Nabeshima K
    Histopathology; 2017 Dec; 71(6):1011-1014. PubMed ID: 28746778
    [No Abstract]   [Full Text] [Related]  

  • 13. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
    Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
    Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse intrapulmonary mesothelioma mimicking pulmonary lepidic adenocarcinoma: a rare case report and review of the literature.
    RanYue W; ChunYan W; Likun H; LiPing Z; JieLu L; ZhengWei D
    Diagn Pathol; 2023 May; 18(1):64. PubMed ID: 37194050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.
    Chiu K; Lee L; Cheung S; Churg AM
    Mod Pathol; 2018 Sep; 31(9):1400-1403. PubMed ID: 29785020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
    Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application and evaluation of EFEMP1 in differential diagnosis of malignant mesothelioma and poorly differentiated adenocarcinoma].
    Wang CS; Meng FQ; Li Q; Wang ZY; Tian L; Wu HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1269-1271. PubMed ID: 38058046
    [No Abstract]   [Full Text] [Related]  

  • 19. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
    Barbieri PG
    Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.